Alvotech Ordinary Shares

ALVO

Alvotech is a global biopharmaceutical company specializing in the development and manufacturing of high-quality biosimilar medicines. Focused on creating affordable alternatives to existing biologic treatments, Alvotech aims to enhance patient access to vital therapies across various therapeutic areas.

$5.23 +0.06 (1.16%)
🚫 Alvotech Ordinary Shares does not pay dividends

Company News

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire Inc. • Rosen Law Firm • January 21, 2026

The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following the company's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, prompting the law firm to prepa...

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Gauzy Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GAUZ
GlobeNewswire Inc. • Rosen Law Firm • January 13, 2026

Rosen Law Firm is soliciting investors who purchased securities of Gauzy Ltd. (NASDAQ: GAUZ) between March 11, 2025 and November 13, 2025 to join a class action lawsuit. The lawsuit alleges that Gauzy made false statements about its business while concealing that three French subsidiaries lacked financial means to meet debts, risking insolvency a...

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire Inc. • Rosen Law Firm • January 13, 2026

The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following the company's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, and investors are being encoura...

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire Inc. • Rosen Law Firm • January 9, 2026

The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following allegations of materially misleading business information. The investigation was triggered by Alvotech's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufact...

Leiðrétting: Viðskipti stjórnenda og tengdra aðila
GlobeNewswire Inc. • Benedikt Stefánsson • January 7, 2026

ATP Holdings ehf. reported transactions in Alvotech shares to Luxembourg's financial regulator CSSF, including the purchase of 4.812.257 shares on December 17 and the sale of 2.110.640 shares on December 19, both at 44.06 SEK per share. A correction was issued regarding the December 19 transaction classification.

Related Companies